Spruce Biosciences Terminates $65M Tildacerfont Collaboration with Kaken, Solidifying Program Discontinuation
SPRB has more than doubled off its 52-week low of $4.275.
Summary
Spruce Biosciences has terminated its collaboration and license agreement with Kaken Pharmaceutical, forfeiting up to $65 million in potential future milestone payments and royalties for its tildacerfont program in Japan. This action follows the company's prior disclosure of discontinuing a key Phase 2 clinical trial for tildacerfont.
Key Events · Financing and Capital Events · SPRB
-
Collaboration Termination
Spruce Biosciences and Kaken Pharmaceutical mutually agreed to terminate their Collaboration and License Agreement for tildacerfont in Japan, effective March 31, 2026.
-
Loss of Future Revenue Potential
The termination results in Spruce Biosciences forfeiting up to approximately $65 million in previously disclosed but unearned milestone payments and royalties from Kaken.
-
Program Discontinuation Confirmed
This action follows a "comprehensive assessment" of the tildacerfont program for CAH and aligns with the company's earlier disclosure in its 10-K from March 9, 2026, of discontinuing a key Phase 2 clinical trial for the asset.
-
No Termination Penalties
Spruce Biosciences incurred no early termination penalties in connection with the Termination Agreement.
Analysis · SPRB · Life Sciences
This 8-K filing confirms the termination of a material collaboration agreement for tildacerfont, a program previously identified as having a discontinued Phase 2 trial. For a company facing "going concern" doubts, the loss of up to $65 million in potential future milestone payments and royalties, while unearned, represents a significant blow to its long-term revenue prospects. This move solidifies the company's strategic pivot away from tildacerfont for CAH, as highlighted in recent corporate updates focusing on its TA-ERT program. Investors should view this as a negative development, further emphasizing the company's need to successfully advance its remaining pipeline assets.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 34.9% of the 999 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SPRB was trading at $58.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.1M. The 52-week trading range was $4.28 to $240.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.